EGFR-TKI联合放疗治疗非小细胞肺癌的效果观察  

Observation on effect of EGFR-TKI combined with radiotherapy in treating non-small cell lung cancer

作　　者：凡治国[1] FAN Zhiguo(Third Department of Internal Medicine,Anyang Municipal Tumor Hospital,Anyang,Henan 455000,China)

机构地区：[1]安阳市肿瘤医院内三科

出　　处：《现代医药卫生》2020年第5期699-701,705,共4页Journal of Modern Medicine & Health

摘　　要：目的探讨表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)联合放疗治疗非小细胞肺癌(NSCLC)患者的效果。方法选取2016年1月至2018年1月在该院治疗的NSCLC患者76例作为研究对象,将其分为观察组(n=36)和对照组(n=40),其中观察组给予EGFR-TKI联合放疗治疗,对照组给予放疗治疗,观察两组治疗疗效及不良反应,采用欧洲癌症治疗研究组织生活质量C30(EORTC QLQ-C30)量表评估患者生活质量。结果观察组近期疗效(治疗总有效率为52.78%)优于对照组的30.00%,差异有统计学意义(P<0.05);观察组中位总体生存时间为15个月[95%可信区间(95%CI):14.44~15.57],明显长于对照组的12个月(95%CI:11.34~12.67),差异有统计学意义(P<0.05);观察组和对照组不良反应发生率比较,差异无统计学意义(P>0.05);观察组治疗后1个月生活质量评分为(59.54±9.22)分,明显低于对照组的(66.67±8.10)分,差异有统计学意义(P<0.05)。结论EGFR-TKI联合放疗治疗NSCLC的效果较好,能延长患者的生存时间,改善其生活质量。Objective To investigate the effect of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)combined with radiotherapy in the treatment of non-small cell lung cancer(NSCLC).Methods Seventy-six patients with NSCLC in this hospital from January 2016 to January 2018 were selected as the study subjects and divided into the observation group(n=36)and control group(n=40).The observation group was given EGFR-TKI combined with radiotherapy,while the control group was treated with radiotherapy.The therapeutic effects and adverse reactions of the two groups were observed.The EORTC QLQ-C30 scale was used to evaluate the quality of life in the patients.Results The short-term curative effect(treatment total effective rate 52.78%)in the observation group was better than 30%in the control group,and the difference was statistically significant(P<0.05).The total median survival time in the observation group was 15 months(95%CI:14.44-15.57),which was significantly longer than 12 months in the control group(95%CI:11.34-12.67),and the difference was statistically significant(P<0.05);there was no statistically significant difference in adverse reactions between the observation group and control group(P>0.05);the quality of life score at 1 months after treatment in the observation group was(59.54±9.22)points,which was significantly lower than(66.67±8.10)points in the control group(P<0.05).Conclusion EGFR-TKI combined with radiotherapy has good effect in the treatment of NSCLC,can prolong the survival time and improve the quality of life.

关 键 词：表皮生长因子受体酪氨酸激酶抑制剂 放疗 非小细胞肺癌 治疗结果 

分 类 号：R5[医药卫生—内科学]